What to expect at EACS 2019

In 2019, the 17th European AIDS Conference (EACS) will be held in Basel, Switzerland, from 6–9 November. The annual meeting attracts key audiences from across the HIV community and is instrumental in shaping the future of HIV science and medicine.

Gilead Sciences, a platinum sponsor for this year’s event, will be at the forefront of helping you translate new developments into daily clinical practice. Join us as we deliver multiple opportunities to participate in real-world, thought-provoking symposia, question leading researchers about new clinical data, and provide you with a unique space where you can meet, learn and share experiences with your peers.

Here’s a snapshot of what you can look forward to.

Gilead Symposium: Together We Can

With the global community focusing on prevention, viral suppression and lifelong good health of people living with HIV (PLHIV), the drive towards the ultimate elimination of HIV is a greater reality.


Together We Can
Wednesday 6th Nov; 15:00- 16:30
San Francisco Room, Basel Congress Center 

This symposium will profile Gilead’s efforts towards the ‘90-90-90’ targets set by UNAIDS in 2014 and addressing the specific needs of key communities. Key thought leaders will share examples of best practice, evolving models of care, and discuss the importance of taking an inclusive approach to stopping the virus and ensuring that no one is left behind.

Gilead Symposium: Hearing Individual Voices

Join us as we explore how patients think and feel at different stages in their HIV journey and discuss how you can tailor treatment to achieve the best possible health outcomes.


Hearing Individual Voices
Friday 8th Nov; 12:15- 13:45
San Francisco Room, Basel Congress Center 

During this symposium we will investigate a variety of patient-related issues and concerns using immersive case studies. These interactions will unveil how patient preferences and physician perspectives can interact and align to effectively manage HIV.

Download your invite to the Symposia

Watch the symposia invite


Gilead Scientific Data

The results from several important studies will be presented at EACS 2019. Consult the table below, which highlights just some of the data being presented, to make sure you’re up-to-date with where and when the latest information will be delivered.

                                                                 Title Location Date/Time
Antiretroviral observational studies
Effectiveness, safety and tolerability of bictegravir /emtricitabine/tenofovir alafenamide (B/F/TAF) in HIV-1 infected adult patients in routine clinical practice – 6 months results of the BICSTaR cohort  

Exhibition Hall


Nov 6,

Antiretroviral randomized clinical trials
Long-term efficacy and safety of bictegravir /emtricitabine/tenofovir alafenamide (B/F/TAF) in ART-naïve adults  

Exhibition Hall


Nov 6,

Co-morbidities, ageing
Switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in adults aged >65 or older: week 48 results from a phase 3b, open-label trial  

Exhibition Hall


Nov 6,

Oral presentations
Antiretroviral therapy in special populations
Efficacy and safety of bictegravir/emtricitabine /tenofovir alafenamide vs comparators in cis-women and girls (living with HIV): an analysis of 5 clinical trials  

Boston 1-3


Nov 7,

Visit the Gilead Booth

Located in Exhibition Space A, the Gilead Booth will be a central hub where you can recharge between sessions, network and interact with colleagues, review a virtual patient case study, and download research articles, including abstracts and/or presentations you may have missed during the year.

We look forward to seeing you at EACS 2019 for what promises to be a unique learning experience.